News

Filter by Year

Mar 04, 2018

London, UK, Carlsbad, CA, 5 March, 2018: GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018, at 2:50 p.m. (EST) at the Boston Marriott Copley Place in…

Feb 26, 2018

London, UK, Carlsbad, CA, February 27, 2018 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for cannabidiol (CBD) for the treatment of tuberous sclerosis (TS). GW is…

Feb 20, 2018

-Study did not meet its primary endpoint-

-Company remains committed to continued development of GWP42006 for autism spectrum disorders and will continue to explore the product’s potential within the field of epilepsy -

London, UK, Carlsbad, CA, February 21, 2018 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical…

Feb 05, 2018

London, UK, Carlsbad, CA, 6 Feb., 2018: GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, will present at the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018, at 2:00 p.m. (EST) at the Lotte New…

Feb 04, 2018

– MAA seeking regulatory approval of Epidiolex for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome –

London, UK, Carlsbad, CA, February 5, 2018 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid product platform, announced…